Key Points
- TriSalus Life Sciences CEO Mary Szela bought 39,682 shares at an average price of $2.59 per share, a transaction worth $102,776.38. After the purchase, she directly owned 1,065,215 shares, according to an SEC filing.
- The stock was up 13.1% and opened at $3.03, while the company’s market cap was about $185.77 million. TriSalus also has a strong current and quick ratio, but continues to post negative earnings.
- Analyst sentiment is mixed: the consensus rating is Hold with an average price target of $7.50. Recent firms have both cut targets and downgraded the stock, while others still rate it a Buy.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) Director Gary Gordon purchased 10,000 shares of the company's stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $2.46 per share, for a total transaction of $24,600.00. Following the transaction, the director directly owned 72,510 shares in the company, valued at approximately $178,374.60. This represents a 16.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
TriSalus Life Sciences Price Performance
TLSI opened at $3.03 on Tuesday. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. The business's fifty day simple moving average is $4.14 and its 200-day simple moving average is $5.11. The company has a market capitalization of $185.76 million, a price-to-earnings ratio of -2.15 and a beta of 0.56.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million. On average, equities research analysts anticipate that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently issued reports on TLSI. Lake Street Capital dropped their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings downgraded shares of TriSalus Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, May 13th. Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, March 6th. Finally, Wall Street Zen upgraded shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $7.50.
View Our Latest Stock Report on TriSalus Life Sciences
Institutional Investors Weigh In On TriSalus Life Sciences
Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company's stock valued at $1,030,000 after acquiring an additional 3,374 shares in the last quarter. Millennium Management LLC boosted its stake in TriSalus Life Sciences by 17.7% in the third quarter. Millennium Management LLC now owns 35,612 shares of the company's stock valued at $166,000 after acquiring an additional 5,359 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after acquiring an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TriSalus Life Sciences in the second quarter valued at approximately $47,000. Finally, Invesco Ltd. acquired a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $72,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
